Posts Tagged ‘Alzheimer's drug’
Alzheimer’s & Dementia researchers challenge FDA’s approval of Aduhelm given lack of evidence for beta-amyloid as a marker
Doctors Blast Biogen Alzheimer Approval as ‘Regulatory Failure’ (Bloomberg): Top researchers who advised the U.S. Food and Drug Administration on Biogen Inc.’s Alzheimer’s drug blasted the agency for approving it, calling the decision a “regulatory failure” that is “at odds with the evidence.”
Read MoreHealth payers–including Medicare and Point32Health–to question Aduhelm pricing and its “reasonable and necessary” use
State’s Second-Largest Health Insurer Slams Biogen For Costly Alzheimer’s Drug (The Boston Globe): The state’s second-biggest health insurer is threatening to limit or not cover Biogen’s new Alzheimer’s drug, accusing the Cambridge biotech of putting “excessive corporate profits” ahead of patients by charging $56,000 a year for the controversial treatment. Michael Sherman, chief medical officer…
Read MoreCan the controversial FDA approval of Aduhelm backfire and delay the discovery of actual Alzheimer’s treatments? (Yes, it can)
The U.S. Food and Drug Administration (FDA) recently approved aducanumab, the first treatment that aims to slow the progression of Alzheimer’s disease. But approval of the drug has provoked mixed reactions from the scientific community. Alzheimer’s disease is characterized by progressive memory loss, spatial disorientation and many other cognitive and behavioural disorders that ultimately lead…
Read More